CJC-1295 (DAC)

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analog of growth hormone-releasing hormone (GHRH). It has been investigated in research for its ability to influence growth hormone secretion, IGF-1 pathways, and related endocrine functions. With the DAC modification, it has also been studied for its extended half-life and potential relevance to areas such as muscle growth and recovery.

Areas of Scientific Interest

• Hormone Regulation — Preclinical studies have examined the ability of CJC-1295 with DAC to stimulate growth hormone release in laboratory models.
• Endocrine Pathways — Research has investigated downstream IGF-1 signaling and associated molecular processes.
• Pharmacokinetics — The DAC modification has been studied for its impact on half-life, stability, and bioavailability in vivo.

Chemical Identity and Properties

• Molecular Formula: C₁₆₅H₂₆₇N₅₁O₅₅
• Molecular Weight: ~3.6 kDa
• Sequence: Tetrasubstituted analog of GHRH with DAC modification
• Appearance: Lyophilized powder
• Purity: ≥99% (HPLC verified)
• Storage: Store in a cool, dry environment; reconstitute only under appropriate laboratory conditions.

Selected Preclinical and Clinical Research

• Journal of Clinical Endocrinology & Metabolism (2006) — Evaluated pharmacokinetics and GH/IGF-1 stimulation.
• Endocrine Reviews (2010) — Discussed long-acting GHRH analogs and their relevance to endocrine research.
• Hormone Research in Paediatrics (2012) — Explored applications of GHRH analogs in growth-related research.

Important Notice

This compound is offered for laboratory research purposes only.

• Not for human consumption, medical, or veterinary use.
• No therapeutic or diagnostic applications are approved.
• All references to published studies are provided for educational purposes only.